<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03857087</url>
  </required_header>
  <id_info>
    <org_study_id>174017</org_study_id>
    <secondary_id>NCI-2018-02331</secondary_id>
    <nct_id>NCT03857087</nct_id>
  </id_info>
  <brief_title>68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer</brief_title>
  <official_title>Gallium-68 Prostate Specific Membrane Antigen for Ovarian Cancer: A Pilot Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radiological Society of North America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen
      (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian
      cancer to detect whether the tumor has spread to other places in the body. 68Ga-PSMA is a
      radioactive substance that binds to blood vessels around the ovarian cancer and can be imaged
      using PET. Diagnostic procedures, such as PET, may help find and diagnose find out how far
      the disease has spread.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the feasibility and utility of 68Ga-PSMA PET imaging patients with ovarian
      cancer.

      II. Determine detection sensitivity for nodal metastases for PSMA PET stratified by node
      size.

      SECONDARY OBJECTIVES:

      I. To assess the correlation between targeted molecular uptake of 68Ga-PSMA PET and PSMA
      expression in surgical resection specimens.

      EXPLORATORY OBJECTIVES:

      I. To explore heterogeneity of 68Ga-PSMA PET uptake in cases of metastatic ovarian cancer.

      II. To determine the relationship between 68Ga-PSMA PET uptake, diffusion weighted imaging,
      and MRI-derived tumor perfusion.

      OUTLINE:

      Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) over 1-2 minutes. After
      about 60 minutes, patients undergo PET/magnetic resonance imaging (MRI) for approximately
      over 50-60 minutes. Patients may undergo an optional repeat gallium Ga 68-labeled PSMA-11 PET
      between 8 and 12 weeks after completion of the first PET/MRI.

      After completion of study, patients are followed up at 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of gallium Ga 68-labeled PSMA-11 positron emission tomography (PET) positive lesions detected by standard staging scans</measure>
    <time_frame>Study Visit Day 1</time_frame>
    <description>Will be descriptively reported for each patient and correlated with the lesions observed in standard imaging computed tomography/magnetic resonance imaging (CT/MRI). In addition, the mean, range, and standard deviation of standardized uptake value maximum (SUVmax) (across all visualized lesions per patient) and SUVmax-average (ave) (across all patients in the study cohort) will be descriptively reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of overall ovarian cancer lesions detected by standard staging scans</measure>
    <time_frame>Study Visit Day 1</time_frame>
    <description>Will be descriptively reported for each patient and correlated with the lesions observed in standard imaging CT/MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average maximum standard uptake value (SUVmax)</measure>
    <time_frame>Study Visit Day 1</time_frame>
    <description>The mean, range, and standard deviation of SUVmax across all visualized lesions per patient will be descriptively reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of lymph nodes detected by PET</measure>
    <time_frame>Study Visit Day 1</time_frame>
    <description>Will be compared and stratified by lymph node size. For patients undergoing surgical resection, this will be compared with the number of involved lymph nodes by surgical resection. For lymph nodes that are not resected, the behavior on follow-up clinical CT scans (if available) will be used to assess for involvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of lymph nodes detected by MRI</measure>
    <time_frame>Study Visit Day 1</time_frame>
    <description>Will be compared and stratified by lymph node size. For patients undergoing surgical resection, this will be compared with the number of involved lymph nodes by surgical resection. For lymph nodes that are not resected, the behavior on follow-up clinical CT scans (if available) will be used to assess for involvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between targeted molecular uptake of 68Ga-PSMA PET and prostate-specific membrane antigen (PSMA) expression in surgical resection specimens</measure>
    <time_frame>Study Visit Day 1</time_frame>
    <description>For patients undergoing surgical resection, the 68Ga PSMA-PET uptake will be correlated with PSMA expression in the primary tumor as well as metastatic sites. PSMA expression measurement is available as a core service from the cancer center</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic 68Ga PSMA PET/MRI</arm_group_label>
    <description>Patients receive gallium Ga 68-labeled PSMA-11 IV over 1-2 minutes. After about 60 minutes, patients undergo PET/MRI for approximately over 50-60 minutes. Patients may undergo an optional repeat gallium Ga 68-labeled PSMA-11 PET between 8 and 12 weeks after completion of the first PET/MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium Ga 68-labeled PSMA-11</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic 68Ga PSMA PET/MRI</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>Given PET/MRI</description>
    <arm_group_label>Diagnostic 68Ga PSMA PET/MRI</arm_group_label>
    <other_name>Magnetic Resonance Imaging</other_name>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging (NMRI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography (PET)</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic 68Ga PSMA PET/MRI</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population will be women with adnexal masses or other lesions suspicious for
        ovarian cancer metastases, who are scheduled for either resection or chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with one of the following, identified on prior imaging (CT, MRI or
             Ultrasound):

               1. adnexal mass

               2. abdominal or pelvic tumor suspicious for ovarian cancer metastases (either
                  suspected on clinical grounds, or known from prior tissue sampling)

          2. Female,

          3. Age &gt;= 18 years

          4. Creatinine &lt;/= 1.5 mg/dL

          5. Ability to understand a written informed consent document, and the willingness to sign
             it

        Exclusion Criteria:

          1. Pregnant or breastfeeding women

          2. Patient unlikely to comply with study procedure, restrictions and requirements and
             judged by the investigator to be unsuitable for study participation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Ohliger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khadija Siddiqua</last_name>
    <phone>877-827-3222</phone>
    <email>Khadija.siddiqua@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khadija Siddiqua</last_name>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Ohliger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Michael Ohliger, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

